Compare BVFL & CNTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BVFL | CNTN |
|---|---|---|
| Founded | 1873 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 183.0M | 146.5M |
| IPO Year | 2023 | 2021 |
| Metric | BVFL | CNTN |
|---|---|---|
| Price | $21.64 | $2.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 7.4K | ★ 579.6K |
| Earning Date | 04-24-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 31.19 | ★ 88.10 |
| EPS | ★ 0.55 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $39.18 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.60 | $1.75 |
| 52 Week High | $22.17 | $5.27 |
| Indicator | BVFL | CNTN |
|---|---|---|
| Relative Strength Index (RSI) | 57.29 | 48.09 |
| Support Level | $20.27 | $1.75 |
| Resistance Level | $21.95 | $2.40 |
| Average True Range (ATR) | 0.38 | 0.16 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 85.40 | 42.55 |
BV Financial Inc is a federally-chartered savings and loan holding company engaged in offering traditional financial services to consumers and businesses. The company offers savings, interest checking, money market, personal and business checking, non-interest checking, education savings, small business checking, and business checking and certificates of deposit and IRA certificates of deposit. It operates in one segment commercial banking. The company's sources of revenue are derived from interest and dividends earned on loans and investment securities.
Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company operates in two reportable segments: digital asset treasury and clinical stage bio-technology. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.